• Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study - The Lancet Infectious Diseases

    Les #Covid_longs sont deux fois moins fréquents chez les infectés entièrement vaccinés.

    We found that the odds of having symptoms for 28 days or more after post-vaccination infection were approximately halved by having two vaccine doses. This result suggests that the risk of #long_COVID is reduced in individuals who have received double vaccination, when additionally considering the already documented reduced risk of infection overall.

  • Twelve-month systemic consequences of #COVID-19 in patients discharged from hospital: a prospective cohort study in Wuhan, China | Clinical Infectious Diseases | Oxford Academic


    Physiological, laboratory, radiological or electrocardiogram abnormalities, particularly those related to renal, cardiovascular, liver functions are common in patients who recovered from COVID-19 up to 12months post-discharge.

    #séquelles #covid_long #long_covid #post_covid

  • Suivi des patients ayant survécu après une hospitalisation pour #covid-19

    1-year outcomes in hospital survivors with #COVID-19: a longitudinal cohort study - The Lancet


    1276 COVID-19 survivors completed both visits [6 months, 12 months]. The median age of patients was 59·0 years (IQR 49·0–67·0) and 681 (53%) were men. The median follow-up time was 185·0 days (IQR 175·0–198·0) for the 6-month visit and 349·0 days (337·0–361·0) for the 12-month visit after symptom onset. The proportion of patients with at least one sequelae symptom decreased from 68% (831/1227) at 6 months to 49% (620/1272) at 12 months (p<0·0001). The proportion of patients with dyspnoea, characterised by mMRC score of 1 or more, slightly increased from 26% (313/1185) at 6-month visit to 30% (380/1271) at 12-month visit (p=0·014). Additionally, more patients had anxiety or depression at 12-month visit (26% [331/1271] at 12-month visit vs 23% [274/1187] at 6-month visit; p=0·015). No significant difference on 6MWD was observed between 6 months and 12 months. 88% (422/479) of patients who were employed before COVID-19 had returned to their original work at 12 months. Compared with men, women had an odds ratio of 1·43 (95% CI 1·04–1·96) for fatigue or muscle weakness, 2·00 (1·48–2·69) for anxiety or depression, and 2·97 (1·50–5·88) for diffusion impairment. Matched COVID-19 survivors at 12 months had more problems with mobility, pain or discomfort, and anxiety or depression, and had more prevalent symptoms than did controls.


    Most COVID-19 survivors had a good physical and functional recovery during 1-year follow-up, and had returned to their original work and life. The health status in our cohort of COVID-19 survivors at 12 months was still lower than that in the control population.


    • Understanding #long_COVID: a modern medical challenge - The Lancet

      Most evidence about long COVID has been limited and based on small cohorts with short follow-up. However, in The Lancet, Lixue Huang and colleagues report 12-month outcomes from the largest longitudinal cohort of hospitalised adult survivors of COVID-19 so far. Including adults (median age 59 years) discharged from Jin Yin-tan Hospital in Wuhan, China, this study advances our understanding of the nature and extent of long COVID.

      At 1 year, COVID-19 survivors had more mobility problems, pain or discomfort, and anxiety or depression than control participants (matched community-dwelling adults without SARS-CoV-2 infection). Fatigue or muscle weakness was the most frequently reported symptom at both 6 months and 12 months, while almost half of patients reported having at least one symptom, such as sleep difficulties, palpitations, joint pain, or chest pain, at 12 months. The study shows that for many patients, full recovery from COVID-19 will take more than 1 year, and raises important issues for health services and research.

      First, only 0·4 of patients with COVID-19 said that they had participated in a professional rehabilitation programme. The reason for such low use of rehabilitation services is unclear, but poor recognition of long COVID and lack of clear referral pathways have been common problems worldwide. Second, the effect of long COVID on mental health warrants further and longer-term investigation. The proportion of COVID-19 survivors who had anxiety or depression slightly increased between 6 months and 12 months, and the proportion was much greater in COVID-19 survivors than in controls. Third, the outcomes from this cohort cannot be generalised to other populations—eg, patients not admitted to hospital, younger people, and those from racially minoritised and other disadvantaged groups who have been disproportionately affected by the pandemic. Research in these populations needs to be prioritised urgently.

      #covid_long #post_covid

  • Thread by chrischirp on Thread Reader App – Thread Reader App

    Prof. Christina Pagel sur Twitter : "#LONG_COVID THREAD:

    The people running the BBC Horizon “Great British Intelligence Test” challenge on over 80,000 people took the opportunity to see if they could detect any differences by whether people had had covid or not..." / Tw


    10. What if by the time there can be no doubt of long term problems in many people who’ve had covid, we’ve allowed millions more infections leaving hundreds of thousands more people affected.

    ONS estimated 634K people with long covid that impacts their life in June.

    11. For comparison, c. 260K people are diagnosed with diabetes & 500K with heart disease each year.

    I worry that we are creating a chronic disease tragedy right now.

    The Silent Pandemic - YouTube

  • #Covid: Children’s extremely low risk confirmed by study - BBC News

    Lead researcher Prof Russell Viner said complex decisions around vaccinating and shielding children required input from many sources - not their work alone.

    But he said if there were adequate vaccines, their research suggested certain groups of children could benefit from receiving Covid jabs.

    He added: “I think from our data, and in my entirely personal opinion, it would be very reasonable to vaccinate a number of groups we have studied, who don’t have a particularly high risk of death, but we do know that their risk of having severe illness and coming to intensive care, while still low, is higher than the general population.”

    He said further vaccine data - expected imminently from other countries, including the US and Israel - should be taken into account when making the decision.

    Dr Elizabeth Whittaker, from the Royal College of Paediatrics and Child Health and Imperial College London, said […] “[a]lthough this data covers up to February 2021, this hasn’t changed recently with the #Delta #variant. We hope this data will be reassuring for children and young people and their families.”

    #enfants #vaccination

  • Pathogens | Free Full-Text | Investigation of #Long_COVID Prevalence and Its Relationship to #Epstein-Barr Virus Reactivation

    Coronavirus disease 2019 (#COVID-19) patients sometimes experience long-term symptoms following resolution of acute disease, including fatigue, brain fog, and rashes. Collectively these have become known as long COVID.

    Our aim was to first determine long COVID prevalence in 185 randomly surveyed COVID-19 patients and, subsequently, to determine if there was an association between occurrence of long COVID symptoms and reactivation of Epstein–Barr virus (#EBV) in 68 COVID-19 patients recruited from those surveyed.

    We found the prevalence of long COVID symptoms to be 30.3% (56/185), which included 4 initially asymptomatic COVID-19 patients who later developed long COVID symptoms.

    Next, we found that 66.7% (20/30) of long COVID subjects versus 10% (2/20) of control subjects in our primary study group were positive for EBV reactivation based on positive titers for EBV early antigen-diffuse (EA-D) IgG or EBV viral capsid antigen (VCA) IgM. The difference was significant (p < 0.001, Fisher’s exact test). A similar ratio was observed in a secondary group of 18 subjects 21–90 days after testing positive for COVID-19, indicating reactivation may occur soon after or concurrently with COVID-19 infection.

    These findings suggest that many long COVID symptoms may not be a direct result of the #SARS-CoV-2 virus but may be the result of COVID-19 inflammation-induced EBV reactivation.

    #covid_long #post-covid

  • The four most urgent questions about long COVID

    It seems unlikely that the virus itself is still at work, says Evans. “Most of the studies have shown that after a few weeks you’ve pretty much cleared it, so I very much doubt it’s an infective consequence.”

    However, there is evidence that fragments of the virus, such as protein molecules, can persist for months7, in which case they might disrupt the body in some way even if they cannot infect cells.

    A further possibility is that long COVID is caused by the immune system going haywire and attacking the rest of the body. In other words, long COVID could be an autoimmune disease. “#SARS-CoV-2 is like a nuclear bomb in terms of the immune system,” says Steven Deeks, a physician and infectious-disease researcher at the University of California, San Francisco. “It just blows everything up.” Some of those changes might linger — as has been seen in the aftermath of other viral infections (see ‘What is the relationship between long COVID and other #post-infection syndromes?’).

    Still, it is too early to say which hypothesis is correct, and it might be that each is true in different people: preliminary data suggest that #long_COVID could be several disorders lumped into one

    #post_covid #auto-immunité

  • Symptoms and Functional Impairment Assessed 8 Months After Mild #COVID-19 Among Health Care Workers | Infectious Diseases | JAMA | JAMA Network

    Symptômes persistant après un Covid_19 léger dans une étude suédoise appelée « COMMUNITY (COVID-19 Biomarker and Immunity) »

    Comparing seropositive vs seronegative participants, 26% vs 9% reported at least 1 moderate to severe symptom lasting for at least 2 months (RR, 2.9 [95% CI, 2.2-3.8]) and 15% vs 3% reported at least 1 moderate to severe symptom lasting for at least 8 months (RR, 4.4 [95% CI, 2.9-6.7]) (Table). The most common moderate to severe symptoms lasting for at least 2 months in the seropositive group were anosmia, fatigue, ageusia, and dyspnea.

    COVID LONG : [Plus d’] 1 patient sur 10 a toujours des symptômes 8 mois après | santé log

    COVID léger ne signifie pas COVID court.

    #covid_long #long_covid

  • Study reveals seven in ten patients hospitalised with #COVID-19 not fully recovered five months post-discharge

    Étude (en cours) #PHOSP-COVID, britannique sur 1077 patients,

    [...] “While the profile of patients being admitted to hospital with COVID-19 is disproportionately male and from an ethnic minority background, our study finds that those who have the most severe prolonged symptoms tend to be white women aged approximately 40 to 60 who have at least two long term health conditions, such as asthma or diabetes.”

    The researchers were able to the classify types of recovery into four different groups or ‘clusters’ based on the participants’ mental and physical health impairments.

    One cluster group in particular showed impaired cognitive function, or what has colloquially been called ‘#brain_fog’. Patients in this group tended to be older and male. Cognitive impairment was striking even when taking education levels into account, suggesting a different underlying mechanism compared to other symptoms.

    [...] much of the wide variety of persistent problems was not explained by the severity of the acute illness - the latter largely driven by acute lung injury - indicating other, possibly more systemic, underlying mechanisms.”

    The research has also uncovered a potential biological factor behind some post-COVID symptoms.

    Professor Louise Wain, GSK/British Lung Foundation Chair in Respiratory Research at the University of Leicester and co-investigator for the PHOSP-COVID study, said: “When we looked at the symptom severity of patients five months after they were discharged from hospital, we found that in all but the mildest cases of persistent post-COVID symptoms, levels of a chemical called C-reactive protein [CRP], which is associated with inflammation, were elevated.

    “From previous studies, it is known that systemic inflammation is associated with poor recovery from illnesses across the disease spectrum. We also know that autoimmunity, where the body has an immune response to its own healthy cells and organs, is more common in middle-aged women. This may explain why post-COVID syndrome seems to be more prevalent in this group, but further investigation is needed to fully understand the processes. The evidence for different recovery ‘clusters’, and ongoing inflammation, really is important in guiding how we conduct further research into the underlying biological mechanisms that drive ‘Long-COVID’.”

    One of the purposes of the PHOSP-COVID study is to measure the impact of medicines given during hospitalisation to see if they affect patients’ recovery. Early indicators from the study show that while giving corticosteroids is a factor in reducing mortality in hospital, it does not appear to have an impact on longer term recovery.


    #long_covid #covid_long #auto-immunité

  •  » Royaume-Uni : Plus d’un patient #Covid sur dix est mort dans les cinq mois suivant sa sortie de l’hôpital

    Plus d’un patient covid sur dix est mort dans les cinq mois suivant la sortie de l’hôpital, tandis que près d’un tiers des personnes ayant survécu au virus ont dû être réadmises, selon de nouvelles recherches.

    Des documents publiés par le groupe consultatif scientifique gouvernemental pour les urgences (le Sage, [ndr : Royaume-Uni]) ont également révélé que la moitié des patients hospitalisés à cause du virus ont souffert de complications, un quart d’entre eux ayant des difficultés une fois à la maison.

    Les jeunes patients de moins de 50 ans sont plus susceptibles de souffrir de complications.

    • Charles Bangham, professeur d’immunologie à l’Imperial College de Londres, a déclaré qu’il pourrait y avoir jusqu’à 50 symptômes de ‘longue covid’, certaines études en ayant trouvé jusqu’à 100.

      Selon lui : « Il est maintenant clair que vaincre une première infection de ce virus n’est pas la fin de l’histoire. Pour une proportion significative de gens, la Covid-19 s’avère être une maladie de longue durée.

      Avec plus de 100 millions de cas de Covid-19 dans le monde, le fardeau sanitaire dû aux longues Covid pourrait être énorme. Rien qu’au Royaume-Uni, des centaines de milliers de patients pourraient présenter des symptômes pendant de nombreux mois, ce qui accentuerait la pression sur un service de santé déjà sous tension.

      Cela aura non seulement un impact sur la vie de ceux qui souffrent, mais pourrait également devenir un fardeau économique permanent s’ils se trouvent dans l’incapacité de travailler. »

      Source : Independent, Shaun Lintern, 19-02-2021

      Traduit par les lecteurs du site Les Crises

      #long_covid #covid-long

    • Vous seriez pas un peu « complotistes », là ? ;-)

      Tiens, à propos, dans la médiasphère, on diffuse à l’envi que la vaccination nous ferait retrouver une vie sociale comme celle « d’avant ». Or, on nous dit aussi que la vaccination nous protège contre les formes GRAVES du Covid mais qu’on peut aussi héberger de la bestiole, donc être re-contaminé et contaminant. Et donc, continuer à porter un masque et pratiquer la « distanciation sociale », c’est à dire vivre avec des avatars numériques et gober tout ce qui est diffusé par les médiacrates. Alors dans ce cas, à quoi sert le vaccin sauf si l’on admet que « un jour » tout le monde (enfin, 99% de tout le monde) sera vacciné ?
      A mon humble avis, on en a pour une décennie.
      Donc la seule stratégie qui aurait prévalu si on avait voulu encore pouvoir se « socialiser », c’est #zéro_covid, comme au Vietnam pour ne citer que ce pays. Le « tester, tracer, isoler », ça ne peut marcher que s’il y a un nombre très limité de cas, pas comme en ce moment où c’est « open bar » pour le virus. Et donc, c’est trop tard à moins d’un confinement dur de plusieurs années pour toute l’Europe. Et là, on peut toujours essayer d’imaginer que l’idée puisse germer dans leurs petites caboches de profiteurs blindés aux as et de jouisseurs hédonistes court-termistes. Les #surnuméraires n’ont qu’à bien se tenir. Nous sommes en train d’assister à une grande manœuvre de #darwinisme_social ... (Mais non, ch’uis pas « complotiste »).

      #Gilles_de_la_Tourette #cojonesvirus

  • Effets à long terme de #COVID-19

    Une méta-analyse sur plusieurs études déjà publiées, incluant près de 48000 patients, a montré que :

    🔴 80% des malades COVID-19 ont développé au moins un symptôme qui persiste sur le long terme après la guérison (durée de suivi maximale de 110 jours)

    🔴 Au moins 55 symptômes ont été identifiés

    🔴 Les cinq symptômes les plus fréquents sont : la fatigue (58 %), les maux de tête (44 %), les troubles de l’attention (27 %), la perte de cheveux (25 %) et la dyspnée (24 %).

    🔰 https://www.medrxiv.org/content/10.1101/2021.01.27.21250617v2.full.pdf

    via Infos Coronavirus Tunisie https://www.facebook.com/groups/218921892639567/permalink/436226764242411
    #long_covid #symptômes_durables

  • Covid-19 : fatigue, faiblesse musculaire, atteintes pulmonaires… trois patients sur quatre présenteraient des symptômes durables

    « The Lancet » a publié samedi une étude portant sur une cohorte de plus de 1 700 patients chinois hospitalisés au printemps 2020, qui montre que 76 % d’entre eux souffraient encore, six mois plus tard, d’au moins un symptôme.

    • 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study - The Lancet

      The long-term health consequences of COVID-19 remain largely unclear. The aim of this study was to describe the long-term health consequences of patients with COVID-19 who have been discharged from hospital and investigate the associated risk factors, in particular disease severity.

      We did an ambidirectional cohort study of patients with confirmed COVID-19 who had been discharged from Jin Yin-tan Hospital (Wuhan, China) between Jan 7, 2020, and May 29, 2020. Patients who died before follow-up, patients for whom follow-up would be difficult because of psychotic disorders, dementia, or re-admission to hospital, those who were unable to move freely due to concomitant osteoarthropathy or immobile before or after discharge due to diseases such as stroke or pulmonary embolism, those who declined to participate, those who could not be contacted, and those living outside of Wuhan or in nursing or welfare homes were all excluded. All patients were interviewed with a series of questionnaires for evaluation of symptoms and health-related quality of life, underwent physical examinations and a 6-min walking test, and received blood tests. A stratified sampling procedure was used to sample patients according to their highest seven-category scale during their hospital stay as 3, 4, and 5–6, to receive pulmonary function test, high resolution CT of the chest, and ultrasonography. Enrolled patients who had participated in the Lopinavir Trial for Suppression of SARS-CoV-2 in China received severe acute respiratory syndrome coronavirus 2 antibody tests. Multivariable adjusted linear or logistic regression models were used to evaluate the association between disease severity and long-term health consequences.

      In total, 1733 of 2469 discharged patients with COVID-19 were enrolled after 736 were excluded. Patients had a median age of 57·0 (IQR 47·0–65·0) years and 897 (52%) were men. The follow-up study was done from June 16, to Sept 3, 2020, and the median follow-up time after symptom onset was 186·0 (175·0–199·0) days. Fatigue or muscle weakness (63%, 1038 of 1655) and sleep difficulties (26%, 437 of 1655) were the most common symptoms. Anxiety or depression was reported among 23% (367 of 1617) of patients. The proportions of median 6-min walking distance less than the lower limit of the normal range were 24% for those at severity scale 3, 22% for severity scale 4, and 29% for severity scale 5–6. The corresponding proportions of patients with diffusion impairment were 22% for severity scale 3, 29% for scale 4, and 56% for scale 5–6, and median CT scores were 3·0 (IQR 2·0–5·0) for severity scale 3, 4·0 (3·0–5·0) for scale 4, and 5·0 (4·0–6·0) for scale 5–6. After multivariable adjustment, patients showed an odds ratio (OR) 1·61 (95% CI 0·80–3·25) for scale 4 versus scale 3 and 4·60 (1·85–11·48) for scale 5–6 versus scale 3 for diffusion impairment; OR 0·88 (0·66–1·17) for scale 4 versus scale 3 and OR 1·77 (1·05–2·97) for scale 5–6 versus scale 3 for anxiety or depression, and OR 0·74 (0·58–0·96) for scale 4 versus scale 3 and 2·69 (1·46–4·96) for scale 5–6 versus scale 3 for fatigue or muscle weakness. Of 94 patients with blood antibodies tested at follow-up, the seropositivity (96·2% vs 58·5%) and median titres (19·0 vs 10·0) of the neutralising antibodies were significantly lower compared with at the acute phase. 107 of 822 participants without acute kidney injury and with estimated glomerular filtration rate (eGFR) 90 mL/min per 1·73 m2 or more at acute phase had eGFR less than 90 mL/min per 1·73 m2 at follow-up.

      At 6 months after acute infection, COVID-19 survivors were mainly troubled with fatigue or muscle weakness, sleep difficulties, and anxiety or depression. Patients who were more severely ill during their hospital stay had more severe impaired pulmonary diffusion capacities and abnormal chest imaging manifestations, and are the main target population for intervention of long-term recovery.

      article complet accessible

      Figure 2Risk factors associated with diffusion impairment and CT score (A), and anxiety or depression and fatigue or muscle weakness (B)
      For associations of age, cigarette smoking, and education with outcome measure, the variables including age, gender, cigarette smoking, education, comorbidity, corticosteroids, antivirals, and intravenous immunoglobulin were all included in the models. For association of comorbidity with outcome, the aforementioned variables were all included together with comorbidity. For association of other factors including sex, corticosteroid, antiviral, and intravenous immunoglobulin with outcome, disease severity and the aforementioned variables were included in the model. OR (95% CI) or β (95% CI) for age indicates the risk of diffusion impairment, CT score, anxiety or depression, and fatigue or muscle weakness per 10-year age increase. OR=odds ratio.

  • #Long_covid

    Les poumons sont l’organe cible de l’infection par le SRAS-CoV-2, et facteur pronostic évident.

    MAIS le virus peut se propager à de nbx organes :
    le cœur, les vaisseaux sanguins, les reins, l’intestin et le cerveau ...

    Des #symptômes persistants sont signalés après la phase aigue du COVID-19, y compris chez les personnes qui souffrent initialement d’une maladie légère.
    –au delà de 12 semaines
    –10-20% des infectés (?)
    Une approche multidisciplinaire est nécessaire


    on sait déja que
    les coronavirus (SARS COV 1 et MERS-CoV)
    Double triangle pointant vers la droite
    Double triangle pointant vers la droite
    persistance de symptômes débilitants

    cf altération des scores de qualité de vie, de santé mentale, à 1 an ds une cohorte canadienne infectée en 2003

    Tansey et al. Arch Intern Med. 2007 ;167(12):1312-1320

    Quels sont les symptômes persistants après COVID 19 ?
    La Cohorte COVICARE suisse a suivi 669 patients ambulatoires entre le 18 mars et le 15 mai.



    Parmi eux, 1/3 souffraient toujours de symptômes à 30-45 jours de l’infection initiale. Parmi les signes les plus fréquents : fatigue, dyspnée, dysosmie/dysgueusie


    mais ATTENTION.

    Il ne faut pas confondre les
    1-symptômes dûs à 1 inflammation chronique persistante
    2- conséquences (csq) des dommages aux organes (lésions de la phase aiguë au cœur / poumon/ cerveau/ reins)

    3- Csq aspécifiques de l’hospitalisation/immobilisation par la maladie/isolement social/SSPT
    4- Effets du déconditionnement périphérique lié au confinement et/ou à la maladie elle-même

    Long covid could be 4 different syndromes, review suggests


    D’ailleurs à quoi seraient dus les symptômes persistants :
    – persistance du virus dans l’organisme / les organes ?
    – réinfection ?
    – dysfonction immunitaire ( système immunitaire affaibli ou surstimulé ) ?
    On ne sait pas exactement (cf SARS)

    Les complications physiques évidentes sont de toutes façons prises en compte en sortie d’hospitalisation. Cela dirigera les patients vers un SSR (quand ils sont dénutris, ont une atteinte neuromusculaire séquellaire...)
    HAS : https://www.has-sante.fr/upload/docs/application/pdf/2020-06/rr_parcours_covid_parcours_de_readaptation_du_patient_covid_-_domicile_mel

    un bilan fonctionnel respiratoire complet est déjà recommandé pour évaluer les séquelles respiratoires (fibrose post SDRA), trois mois après la sortie de l’hôpital

    quelles sont les données de la littérature sur les symptômes de #LongCovid et leur origine/étiologie ?

    atteinte neurologique (1/2) :
    ~ 10 à 35% souffrent de symptômes persistants, principalement neurologiques : dysfonctionnement du système nerveux autonome, troubles du sommeil, syndromes douloureux, étourdissements, difficultés cognitives.


    atteinte neurologique (2/2) : origine ?

    – invasion virale directe du SNC par SARS COV2
    – réponse immunitaire à médiation virale

    Emerging Neurological and Psychobiological Aspects of COVID-19 Infection


    atteinte respiratoire (1/2) :
    ~ 30% des patients hospitalisés après la phase aigue
    * atteinte TDM et de fonction respiratoire s’améliore au cours du suivi
    Recovery after COVID-19 – an observational prospective multi-center trial


    atteinte respiratoire (2/2) :
    pour les patients ambulatoires c’est moins clair :
    *intolérance à l’effort
    *douleurs thoraciques

    dysfonction autonomique (1/2) : prévalence non connue
    ~ syndrome d’intolérance orthostatique
    – palpitations
    – dyspnée
    – douleurs thoraciques
    – hypotension orthostatique
    – syncope

    dysfonction autonomique (2/2) physiopathiologie :
    – conséquence de l’orage cytokinique ?
    – Atteinte directe du système nerveux autonome par le coronavirus ?
    – déconditionnement ou hypovolémie ?
    – neuropathie à médiation immunitaire ou virale ?


    atteinte cardiaque (1/2) : risque de maladie cardiovascu.
    Flèche nord-est
    suite à 1 infection à coronavirus, MAIS l’att. myocardique persistante n’est pas avérée pour SARS COV2 malgré la présence (autopsie) de virus dans cellules

    update on COVID-19 Myocarditis


    atteinte cardiaque (2/2) : arythmies persistantes
    ~ tachycardie sinusale inappropriée
    – hyperactivité intrinsèque du nœud sinusal,
    – dysfonctionnement autonome
    – état hyperadrénergique

    Management of Arrhythmias Associated with COVID-19

    atteinte digestive ~ 35% des patients à la phase aigue.
    tube digestif : taux élevé d’ACE2, le récepteur de liaison au SRAS-COV-2,
    = site d’infection virale efficace
    = site d’excrétion virale périodique

    Symptômes persistants peu étayés


    atteinte cutanée
    Plutôt à la phase aigue = lésions acrales ~ pseudo-engelures, éruptions érythémateuses maculopapuleuses, éruptions vésiculaires, des éruptions urticariennes, des éruptions vasculaires

    An Evidence-Based Review

    en CCL :
    –symptômes (liste non exhaustive) persistants de #LongCovid nombreux
    – physiopathologie n’est pas élucidée
    – études de cohorte sont donc NECESSAIRES
    –avec une action COORDONNEE de recherche/prise en charge sur notre territoire


    #covid-19 #covid #séquelles #maladie #coronavirus

  • Damage to multiple organs recorded in ’#long_Covid' cases | World news | The Guardian

    Des dommages affectant plusieurs organes détectés chez des jeunes atteints du #coronavirus French.news.cn

    LONDRES, 15 novembre (Xinhua) — Des signes de dommages affectant plusieurs organes ont été détectés chez certains individus jeunes et auparavant en bonne santé présentant des symptômes persistants de coronavirus quatre mois après leur infection initiale, révèle une étude britannique.

    Cette étude de #Coverscan visait à évaluer l’impact à long terme du #COVID-19 sur les organes auprès de quelque 500 personnes « à faible risque » - principalement des individus relativement jeunes présentant des symptômes persistants de coronavirus, mais n’ayant pas de problème de santé sous-jacent majeur, a rapporté dimanche le journal britannique, le Guardian.

    Les données préliminaires récoltées auprès des 200 premiers patients suggèrent que quatre mois après l’infection initiale, près de 70 % des malades présentent des dommages à un ou plusieurs organes, dont le cœur, les poumons, le foie et le pancréas.

    « La bonne nouvelle, c’est que les déficiences observées sont légères. Mais même en utilisant des critères larges, il y a bel et bien des déficiences, et chez 25 % des personnes, elles affectent deux organes ou plus », a déclaré Amitava Banerjee, cardiologue et professeur associé de science des données cliniques à l’université de Londres.

    « C’est un phénomène qui nous intéresse, car nous devons savoir si (ces dommages) persistent ou guérissent, ou même s’il existe un sous-groupe de personnes chez qui ils pourraient s’aggraver », a indiqué M. Banerjee.